Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04528082

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease

The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.

Recruiting

Interested in participating?

Request Info

Key information

Age range

2 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hospices Civils de Lyon Hopital Femme Mere Enfant, Bron, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria

  • Male or Female participants 2 to < 18 years of age at randomization.
  • Diagnosed with BD meeting the ISGBD criteria at any time prior to the screening visit.
  • Oral ulcers that occurred ≥ 3 times within the 12-month period prior to the screening visit.
  • Participant must have ≥ 2 oral ulcers at both the screening visit and on day 1.
  • Participant has had prior treatment with ≥ 1 non-biologic BD therapy, such as, but not limited to, topical corticosteroids or systemic treatment.

Key Exclusion Criteria

  • Behçet's disease-related active major organ involvement - pulmonary (eg, pulmonary artery aneurysm), vascular (eg, thrombophlebitis), gastrointestinal (eg, ulcers along the gastrointestinal tract), or CNS (eg, meningoencephalitis) manifestations, or ocular lesions (eg, uveitis) requiring immunosuppressive therapy; however:
  • Previous major organ involvement is allowed if it occurred ≥1 year prior to the screening visit and is not active at time of enrollment
  • Participants with mild BD-related ocular lesions not requiring systemic immunosuppressive therapy are allowed
  • Participants with BD-related arthritis and BD-skin manifestations are also allowed.
  • Previous exposure to biologic therapies for the treatment of BD oral ulcers, previous biologic exposure is allowed for other indications (including other manifestations of BD).

Treatment and study plan

Apremilast

Drug

Participants will receive apremilast orally.

Other names: Otezla®

Placebo

Drug

Participants will receive the matching placebo orally.

Primary outcomes

  1. Area Under the Curve for the Number of Oral Ulcers from Week 0 Through Week 12 (AUCw0-12)

    Time frame: Week 0 to Week 12

Secondary outcomes

  1. Number of Oral Ulcers from Week 0 to Week 12

    Time frame: Week 0 to Week 12

  2. Change from Week 0 to Week 12 in the Pain of Oral Ulcers in Participants 5 Years of Age and Older

    Time frame: Week 0 to Week 12

    Pain of oral ulcers will be measured by a visual analog scale (VAS). The participants will be asked to place a vertical line on a 100 mm VAS at the point that represents the severity of oral ulcer pain. The scale will range from "no pain" (left hand boundary) to "worst possible pain" (right hand boundary).

  3. Complete Response Rate for Oral Ulcers

    Time frame: Week 12

    Complete response rate for oral ulcers is defined as the proportion of participants who are oral ulcer free at Week 12.

  4. Proportion of Participants at Week 12 Whose Number of Oral Ulcers is Reduced by Greater Than or Equal to 50% from Week 0

    Time frame: Week 0 to Week 12

  5. Complete Response Rate for Genital Ulcers

    Time frame: Week 12

    Complete response rate for genital ulcers is defined as the proportion of participants (with genital ulcers at week 0) who are genital ulcer free at Week 12.

  6. Change from Week 0 to Week 12 in Disease Activity

    Time frame: Week 0 to Week 12

    Disease activity is measured by Behçet's Disease Current Activity (BDCAF) scores. The BDCAF consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening), and a negative change from baseline indicates improvement. The Patient's Perception of Disease Activity and the Clinician's Overall Perception of Disease Activity were assessed by the subject and the clinician, respectively, using a scale of 1 to 7, where a higher score indicates a higher level of disease activity.

  7. Proportion of Participants at Week 12 Who Have New-onset or Recurrence of Behçet's-related Manifestations (Other than Oral and Genital Ulcers)

    Time frame: Week 12

  8. Change from Week 0 to Week 12 on the Short Form Survey (SF-10)

    Time frame: Week 0 to Week 12

    The SF-10 Health Survey for Children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire. The SF-10 is intended to produce physical and psychosocial health summary measures. Each of the 10 questions responses is scored with a point value from 1 to 6 (1 is the worst possible condition and 6 is the best possible condition). The SF-10 physical and psychosocial measures are scored such that higher scores indicate more favorable functioning.

  9. Number of Participants with a Treatment-emergent Adverse Event

    Time frame: Up to Week 56

  10. Occurrence, Severity, and Frequency of Suicide/Suicide-related Ideations and Behaviors as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to Week 56

    The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior is defined as the number of participants who answer "yes" at any time during the study (up to end of safety follow-up, Week 56) to one of the 10 categories:

    Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide

  11. Change from Week 0 to Week 52 in Tanner Staging

    Time frame: Week 0 to Week 52

    Tanner Staging of sexual development assessment will be used to assess sexual maturity. Tanner Staging assessment consists of 3 domains (pubic hair, breast development, and other changes) for girls and 4 domains (pubic hair, penis development, testes development, and other changes) for boys. Stages range from 1-5, with 1 indicating preadolescent and 5 adult.

  12. Change in Body Weight Measurements

    Time frame: Week 0 to Week 56

  13. Change in Height Measurements

    Time frame: Week 0 to Week 56

  14. Change in Body Mass Index (BMI)

    Time frame: Week 0 to Week 56

    BMI assessed as weight/(height/100)^2

  15. Plasma Concentrations of Apremilast

    Time frame: Up to Week 52

  16. Taste and Acceptability of Apremilast

    Time frame: Week 0 and Week 2

    Taste and acceptability will be assessed using a questionnaire with a 7-point faces Likert Scale, with 1 ranging from "super bad" to 7 "super good" and questions to determine whether the participants are able to take the treatment medication.

  17. Proportion of Participants Who Require Protocol-prohibited Medications due to Worsening of Behçet's Disease

    Time frame: Week 0 to Week 12

Study contacts

Contact information is provided by the study sponsor or research team.

Amgen Call Center

CONTACT

[email protected]

866-572-6436

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN)

Acronym: BEAN

Important dates

Study start
2021
Primary completion
2030
Study completion
2030
First posted
Aug 27, 2020
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.